

#### DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS



20 APR 2017

MEMORANDUM FOR SGOM

ATTN: CAPT JEAN STOREY

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- Your paper, entitled <u>Six Years Experience with Porcine Extracellular Matrix: A New Paradigm for Pelvic Floor Repair</u> presented at/published to <u>ACOG Annual Clinical Meeting</u>, <u>La Jolla</u>, <u>CA</u>, 6-9 <u>May 2017</u> in accordance with MDWI 41-108, has been approved and assigned local file #<u>17171</u>.
- 2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist's Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.
- 4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC Director, Clinical Investigations & Research Support

inda Steel-Goodwin

### PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

## INSTRUCTIONS USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

- 1. The author must complete page two of this form:
  - a. In Section 2, add the funding source for your study [ e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D;
     Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed
     Medical Research Program (CDMRP); Grants; etc.]
  - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
  - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). If you have any questions or concerns, please contact the 59 CRD/ Publications and Presentations Section at 292-7141 for assistance.
- 8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- 10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:
  - "The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:
  - "The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02\_AFI 40-402."
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401 IP:
  - "The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFES	SIONAL MEDICAL	RESE	ARCH/TECHNICAL	PUBLICATI	ONS/PRE	SENTATIONS	
1. TO: CLINICAL RESEARCH 2. FROM: (A	uthor's Name, Rank, Gra	ade, Offi	ce Symbol)			4. PROTOCOL NUMBER:	
1 7	Capt, O3, SGOM			XES [	¬	N/A	
5. PROTOCOL TITLE: (NOTE: For each new		arch or	achainal information		-		
must be submitted fo	r review and approval.)	alcii ui i	ecimical information as a	publication/pres	sentation, a r	new 59 MDW Form 3039	
N/A		24					
6. TITLE OF MATERIAL TO BE PUBLISHED							
Six Years Experience with Porcine Extra				Repair			
7. FUNDING RECEIVED FOR THIS STUDY?	AND STATE OF THE S						
8. DO YOU NEED FUNDING SUPPORT FOR		SES: [	YES NO		-		
9. IS THIS MATERIAL CLASSIFIED? YE							
10. IS THIS MATERIAL SUBJECT TO ANY LI AND DEVELOPMENT AGREEMENT (CRADA YES NO <b>NOTE</b> : If the answer is YE	.), MATERIAL TRANSFE	R AGRE	EEMENT (MTA), INTELLI	ECTUAL PROPE	RTY RIGHT	S AGREEMENT ETC.?	
11. MATERIAL IS FOR: DOMESTIC REL CHECK APPROPRIATE BOX OR BOXES				PY OF MATERIA	AL TO BE P	IRI ISHED/PRESENTED	
11a. PUBLICATION/JOURNAL (List into	ended publication/journa	l.)	Legisti il mondo	TO MATERIA	AL TO BE F	DBLISHED/FRESENTED.	
11b. PUBLISHED ABSTRACT (List inte	nded journal.)						
11c. POSTER (To be demonstrated at a ACOG Annual Clinical Meeting, La			tate, and date of meeting	.)			
11d. PLATFORM PRESENTATION (At	civilian institutions: name	e of mee	ting, state, and date of m	eting.)			
11e. OTHER (Describe: name of meeting	ig, city, state, and date o	f meetin	g.)				
12. EXPECTED DATE WHEN YOU WILL NEI NOTE: All publications/presentations are	ED THE CRD TO SUBM required to be placed in	IT YOUR	R CLEARED PRESENTA	TION/PUBLICAT	TION TO DT	IC	
DATE							
15Apr2017							
13. 59 MDW PRIMARY POINT OF CONTACT	/ ast Name First Name	9 M L 4	mail)		14 DUTY	DUONE/DACED NUMBER	
Storey, Jean V - jean.v.storey.mil@mail.mil					Tanana managana managa	14. DUTY PHONE/PAGER NUMBER 916-6463/513-2905	
15. AUTHORSHIP AND CO-AUTHOR(S) List		poor in t	no monuscript		910-0403	0/313-2903	
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK		SQUADRON/GROUP/OF	FICE SYMBOL	INST	ITUTION (If not 59 MDW)	
Primary/Corresponding Author     Storey, Jean V	O3/Capt		CSPS/SGOM 59 MDW		,		
b. Kambiss, Scott M	06/COL				BAM	C	
c.							
d.						1107 1107 1107 1107 1107 1107 1107 1107	
e.							
f.							
I CERTIFY ANY HUMAN OR ANIMAL RESEA 219, AFMAN 40-401_IP, AND 59 MDWI 41-10 ACCURATE MANUSCRIPT FOR PUBLICATION	8. I HAVE READ THE F	INAL VE	E APPROVED AND PER RSION OF THE ATTAC	FORMED IN STI HED MATERIAL	RICT ACCO AND CERT	RDANCE WITH 32 CFR IFY THAT IT IS AN	
16. AUTHOR'S PRINTED NAME, RANK, GRADE		17. AUTHOR'S SIGNATURE			18. DATE		
Jean Storey, Capt, O3		STOREY.JEAN.V.1141148695 The roll, the 18 through and the control and the cont		01Apr2017			
19. APPROVING AUTHORITY'S PRINTED NA	ME, RANK, TITLE		20. APPROVING AUTHORITY'S SIGNATUR		ATURE	21. DATE	
Larissa F. Weir, MD, Maj, USAF, MC Residency Prg Director			WEIR LARISSA F. 1255719021  WEIR LARISSA F. 1255719021  On the control of the con			01APR2017	

PROCESSING OF PROFES	SIONAL MEDICAL RE	ESEARCH/TECHNICAL BURLICATIONS/DD	ECENTATIONS			
1st ENDORSEMENT (59 MDW/SGVU Use O	only)	ESEARCH/TECHNICAL PUBLICATIONS/PR	ESENTATIONS			
TO: Clinical Research Division	22. DATE RECEIVED	23. ASSIGNED PROCESSING REQUEST FILE	NUMBER			
59 MDW/CRD Contact 292-7141 for email instructions.	March 31, 2017	17171				
24. DATE REVIEWED		25. DATE FORWARDED TO 502 ISG/JAC	25. DATE FORWARDED TO 502 ISG/JAC			
April 07, 2017						
26. AUTHOR CONTACTED FOR RECOMME	ENDED OR NECESSARY CH	HANGES: NO YES If yes, give date.	N/A			
	SAPPROVED					
Research presentation with determination policy presentation is cleared. Appropria	n from SAMMC IRB as c ate disclaimers included	case series report. AIO notified of protest, but in a	ccordance with local			
28. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	29. REVIEWER SIGNATURE	30. DATE			
Kevin Kupferer/GS13/Human Research			April 07, 2017			
2nd ENDORSEMENT (502 ISG/JAC Use Onl		One 2017 In 16 15 6 20 4000	April 07, 2017			
31. DATE RECEIVED	7)	32. DATE FORWARDED TO 59 MDW/PA	32. DATE FORWARDED TO 59 MDW/PA			
34. PRINTED NAME, RANK/GRADE, TITLE (	OF REVIEWER	35. REVIEWER SIGNATURE	36. DATE			
3rd ENDORSEMENT (59 MDW/PA Use Only)	1					
37. DATE RECEIVED		38. DATE FORWARDED TO 59 MDW/SGVU				
April 18, 2017		April 20, 2017	April 20, 2017			
39. COMMENTS   APPROVED (In comp		cy review directives.) DISAPPROVED				
40. PRINTED NAME, RANK/GRADE, TITLE O		41. REVIEWER SIGNATURE	42. DATE			
Kevin Iinuma, SSgt/E-5, 59 MDW Public		Digitally signed by IRAMA KEVAN HT SUCU 129K227613. DN evids on U.S. Government, our Doc Our PRIL, our USAF, onr BRUMA KEVAN MITSUGU 129K227613. Date: 2017 04 20:10:48-46-00507.	April 20, 2017			
4th ENDORSEMENT (59 MDW/SGVU Use Or						
43. DATE RECEIVED		SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVA  YES NO COULD NOT BE REACHED L	L OR DISAPPROVAL LEFT MESSAGE			
45. COMMENTS APPROVED DIS	APPROVED					
46. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER		47. REVIEWER SIGNATURE	48. DATE			




Six Years Experience with Porcine Extracellular Matrix: A New Paradigm for Pelvic Floor Repair Jean V Storey, DO, Capt, USAF, MC; Scott Kambiss, DO, COL, MC, USA; Raúl Yordán-Jovet, MD, LtCol (Ret), USAF, MC San Antonio Uniformed Services Health Education Consortium, TX

## USAF, MC

#### BACKGROUND

- Pelvic organ prolapse (POP) can be associated with sexual, defecatory, and urinary dysfunction
- 3<sup>rd</sup> most common reason for hysterectomy and an 11% lifetime-risk of surgery for POP
- · 30% re-operation after initial surgery
- Native tissue augmentation includes synthetic mesh or biologic-derived graft which can increase durability and longevity of repair
- Significant complications including dyspareunia, contractions, erosions and fistulas appear material-dependent

#### **Tissue Augmentation Options**



#### Porcine Extracellular Matrix







Figure 2 - At Placement

#### Methods

- · Case Series
  - 84 patients with Porcine Extracellular Matrix
  - Variety of level 1 and 2 defects
- Outcome
- Support (POP-Q @ 3 mos)
- Durability of repair (POP-Q yearly)
- Intra / Postoperative complications
- Charts at our institution between 2010-2015 were reviewed
- Preoperative POP-Q scores measuring level 1 and level 2 support ranged from -2 to +6 at most presenting part
- Total of 93 pelvic reconstruction procedures performed:
- 61 anterior repairs
  - Includes 17 TVHs with uterosacral ligament suspension and 6 concurrent posterior repairs
- 27 additional posterior repairs
- 2 vaginal paravaginal repairs
- 3 bilateral sacrospinous colpopexies

#### REFERENCES

- Hendry SL, Clark A. Nypard I. Aregali A. Barnebe V. McTernan A. Penic organ prosper in the Women: Health Infestice grants and graviting. Am J Clarkd Gymeol 2002. Jun 18(3): 1100-8.
   Bart Di Lond B. Barnes Research annual processing.
- methor remodeling amount to Lingment J 2011, Jan. 27 601–602.

  3. Abrein D. Vaymen T. Engli ME. Asstein S. Falconer C. Asterior colorathicity versus transparent each financial service.
- Abrein D, Veymann T, Engli ME, Assisser S, Falconer C. Anterior zolporthaphy versus trans-aginal mesh fil pathologies in Pengli Med 2011. May 504(19):1806-58.
- 4. Cetry M. Hagel P. Coh J. Lim J. Long A. Roude H. Comiss A Tragent inper-with meth versus exportance for professe a retractment for commission. In 1970 (2015) the 1970 (2015) The 1970 (2015) of the
- The view(s) expressed herein are those of the authorisised do not reflect the official policy or position of Brook Army Medical Centar, the U.S. Army Medical Department, the U.S. Army Medical Department of the Army or the Surgeon General, the Department of the Ar. Force, the Department of the Army or the Department of Definition or the U.S. Government.

#### Results

- POP-Q scores obtained from 3-72 months (median = 54) postoperatively
- Durable global level 1 and 2 support with most patient at -3 scores at presenting part
- No significant surgical or product complications were identified
- Postoperative
- 2 anatomical failures to anterior or apical scores of -1 at most presenting part
- Only 1 symptomatic case needed reoperation (enterocele)

#### CONCLUSION

- Porcine Extracellular Matrix
  - Is technically easy to use
  - Provides durable POP repair
  - No complications associated with matrix
  - No host-graft rejection
- Limitations
  - · Observational case series
  - · No controls or randomization
- Future Directions
  - Prospective trial comparing autologous and absorbable xenograft repairs
- · QoL evaluation
- · Cost effectiveness evaluation

# Scan Log

## E-mail Sent

Date: Monday, 2017-04-24 06:48

To: linda.steelgoodwin.mil@mail.mil

From: 4430-133A@us.af.mil

Subject: Message:

Attachments: image2017-04-24-064826.pdf